Last reviewed · How we verify
Pegvisomant treatment
At a glance
| Generic name | Pegvisomant treatment |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Pasireotide Lar Therapy on Bone Metabolism
- PegvisOMant and the Immune SystEm (PROMISE)
- Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
- Acromegaly Combination Treatment Study (NA)
- Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?
- Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients (PHASE3)
- Strict IGF-1 Control in Acromegaly (PHASE3)
- Bone MicroArchitecture in Acromegaly
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegvisomant treatment CI brief — competitive landscape report
- Pegvisomant treatment updates RSS · CI watch RSS
- Pfizer portfolio CI